| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 44 | 2025 | 326 | 11.320 |
Why?
|
| Colitis, Ulcerative | 23 | 2024 | 217 | 6.340 |
Why?
|
| Crohn Disease | 23 | 2024 | 286 | 6.290 |
Why?
|
| Natural Language Processing | 7 | 2022 | 70 | 1.660 |
Why?
|
| Veterans | 10 | 2022 | 1779 | 1.580 |
Why?
|
| Colorectal Neoplasms | 7 | 2022 | 650 | 1.500 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2018 | 315 | 1.490 |
Why?
|
| United States Department of Veterans Affairs | 11 | 2024 | 707 | 1.270 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2023 | 702 | 1.160 |
Why?
|
| Critical Pathways | 2 | 2019 | 79 | 1.090 |
Why?
|
| Biosimilar Pharmaceuticals | 2 | 2024 | 6 | 1.020 |
Why?
|
| Gastrointestinal Agents | 2 | 2017 | 67 | 0.960 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2019 | 145 | 0.960 |
Why?
|
| Colitis | 2 | 2020 | 173 | 0.950 |
Why?
|
| Colonoscopy | 5 | 2022 | 249 | 0.920 |
Why?
|
| Quality Indicators, Health Care | 2 | 2019 | 232 | 0.900 |
Why?
|
| Gastroenterology | 5 | 2024 | 210 | 0.890 |
Why?
|
| Quality Improvement | 4 | 2020 | 695 | 0.890 |
Why?
|
| United States | 31 | 2024 | 11711 | 0.890 |
Why?
|
| International Classification of Diseases | 2 | 2016 | 100 | 0.890 |
Why?
|
| Immunocompromised Host | 2 | 2018 | 306 | 0.850 |
Why?
|
| Biological Products | 3 | 2023 | 137 | 0.830 |
Why?
|
| Humans | 90 | 2025 | 133736 | 0.830 |
Why?
|
| Middle Aged | 42 | 2024 | 29298 | 0.800 |
Why?
|
| Anxiety | 2 | 2020 | 991 | 0.770 |
Why?
|
| Immunosuppressive Agents | 5 | 2022 | 694 | 0.760 |
Why?
|
| Radiation Dosage | 2 | 2013 | 145 | 0.760 |
Why?
|
| Aged | 34 | 2024 | 21680 | 0.750 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2021 | 473 | 0.740 |
Why?
|
| Diet | 5 | 2019 | 1191 | 0.740 |
Why?
|
| Digestive System Surgical Procedures | 4 | 2021 | 89 | 0.730 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 648 | 0.690 |
Why?
|
| Gastrointestinal Microbiome | 5 | 2021 | 824 | 0.670 |
Why?
|
| Cost of Illness | 2 | 2024 | 276 | 0.660 |
Why?
|
| Male | 50 | 2025 | 65867 | 0.660 |
Why?
|
| Depression | 2 | 2020 | 1356 | 0.650 |
Why?
|
| Veterans Health | 5 | 2021 | 179 | 0.640 |
Why?
|
| Gastrointestinal Diseases | 2 | 2014 | 361 | 0.640 |
Why?
|
| Adult | 35 | 2025 | 31880 | 0.630 |
Why?
|
| Hematinics | 1 | 2019 | 60 | 0.590 |
Why?
|
| Female | 46 | 2025 | 71617 | 0.590 |
Why?
|
| Age of Onset | 2 | 2016 | 636 | 0.570 |
Why?
|
| Databases, Factual | 4 | 2018 | 1242 | 0.560 |
Why?
|
| Intestinal Mucosa | 6 | 2021 | 815 | 0.560 |
Why?
|
| Virus Activation | 1 | 2018 | 85 | 0.560 |
Why?
|
| Hepatitis B virus | 1 | 2018 | 142 | 0.540 |
Why?
|
| Gastric Acid | 1 | 2017 | 56 | 0.530 |
Why?
|
| Transition to Adult Care | 1 | 2019 | 119 | 0.530 |
Why?
|
| Colonic Neoplasms | 1 | 2020 | 271 | 0.530 |
Why?
|
| Histamine H2 Antagonists | 1 | 2017 | 50 | 0.530 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2023 | 284 | 0.520 |
Why?
|
| Hepatitis B | 1 | 2018 | 173 | 0.510 |
Why?
|
| Tuberculin Test | 1 | 2017 | 123 | 0.500 |
Why?
|
| Fissure in Ano | 1 | 2015 | 6 | 0.490 |
Why?
|
| Latent Tuberculosis | 1 | 2017 | 76 | 0.490 |
Why?
|
| Risk Factors | 17 | 2022 | 11114 | 0.490 |
Why?
|
| Algorithms | 6 | 2022 | 1733 | 0.490 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 65 | 0.480 |
Why?
|
| Quality of Life | 5 | 2025 | 2150 | 0.480 |
Why?
|
| Colon | 5 | 2021 | 379 | 0.470 |
Why?
|
| Stress, Psychological | 2 | 2017 | 601 | 0.470 |
Why?
|
| Radiation Injuries | 2 | 2020 | 166 | 0.460 |
Why?
|
| Proton Pump Inhibitors | 2 | 2018 | 285 | 0.460 |
Why?
|
| Behavior Therapy | 1 | 2017 | 268 | 0.450 |
Why?
|
| Spondylarthritis | 2 | 2025 | 7 | 0.440 |
Why?
|
| Gastroenterologists | 2 | 2024 | 12 | 0.440 |
Why?
|
| Retrospective Studies | 19 | 2022 | 17423 | 0.440 |
Why?
|
| Cohort Studies | 10 | 2022 | 5195 | 0.430 |
Why?
|
| Scedosporium | 1 | 2013 | 7 | 0.420 |
Why?
|
| Disease Management | 2 | 2017 | 564 | 0.420 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2024 | 905 | 0.420 |
Why?
|
| Diet Therapy | 1 | 2013 | 43 | 0.410 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2020 | 646 | 0.410 |
Why?
|
| Logistic Models | 6 | 2020 | 1908 | 0.410 |
Why?
|
| Brain Abscess | 1 | 2013 | 54 | 0.400 |
Why?
|
| Infliximab | 3 | 2022 | 68 | 0.400 |
Why?
|
| Frontal Lobe | 1 | 2013 | 122 | 0.400 |
Why?
|
| Safety-net Providers | 1 | 2013 | 62 | 0.400 |
Why?
|
| Leukopenia | 1 | 2012 | 48 | 0.390 |
Why?
|
| Mycoses | 1 | 2013 | 118 | 0.380 |
Why?
|
| Barrett Esophagus | 4 | 2022 | 355 | 0.380 |
Why?
|
| Medical Audit | 1 | 2012 | 104 | 0.380 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1415 | 0.370 |
Why?
|
| Digestive System Neoplasms | 1 | 2011 | 14 | 0.370 |
Why?
|
| Health Personnel | 1 | 2017 | 543 | 0.370 |
Why?
|
| Caregivers | 1 | 2017 | 586 | 0.370 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2014 | 200 | 0.370 |
Why?
|
| Prevalence | 5 | 2021 | 2667 | 0.360 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2011 | 86 | 0.360 |
Why?
|
| Proctitis | 1 | 2011 | 6 | 0.360 |
Why?
|
| Diarrhea | 1 | 2013 | 342 | 0.360 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2020 | 341 | 0.360 |
Why?
|
| Lichen Planus, Oral | 1 | 2010 | 2 | 0.350 |
Why?
|
| Endoscopy | 1 | 2013 | 287 | 0.350 |
Why?
|
| Young Adult | 12 | 2023 | 9874 | 0.350 |
Why?
|
| Androstadienes | 1 | 2010 | 52 | 0.340 |
Why?
|
| Practice Guidelines as Topic | 4 | 2014 | 1339 | 0.340 |
Why?
|
| Cryosurgery | 1 | 2011 | 48 | 0.340 |
Why?
|
| Treatment Outcome | 8 | 2025 | 13005 | 0.340 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2010 | 45 | 0.330 |
Why?
|
| Health Care Costs | 2 | 2024 | 407 | 0.320 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 1492 | 0.310 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 317 | 0.310 |
Why?
|
| Endoscopy, Gastrointestinal | 4 | 2020 | 244 | 0.300 |
Why?
|
| Immunologic Factors | 2 | 2023 | 184 | 0.300 |
Why?
|
| Deglutition Disorders | 1 | 2010 | 147 | 0.300 |
Why?
|
| Odds Ratio | 5 | 2020 | 1338 | 0.300 |
Why?
|
| Remission Induction | 2 | 2025 | 308 | 0.300 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 7196 | 0.300 |
Why?
|
| Cross-Sectional Studies | 8 | 2021 | 3743 | 0.280 |
Why?
|
| Quality Assurance, Health Care | 2 | 2021 | 222 | 0.270 |
Why?
|
| Postoperative Complications | 2 | 2021 | 3167 | 0.270 |
Why?
|
| Program Evaluation | 3 | 2019 | 455 | 0.270 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2024 | 3479 | 0.260 |
Why?
|
| Incidence | 5 | 2021 | 3402 | 0.250 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2025 | 207 | 0.250 |
Why?
|
| Age Factors | 5 | 2019 | 2990 | 0.250 |
Why?
|
| Drug Prescriptions | 3 | 2024 | 238 | 0.250 |
Why?
|
| Prednisone | 2 | 2021 | 288 | 0.250 |
Why?
|
| Fetus | 1 | 2009 | 599 | 0.240 |
Why?
|
| Peptic Ulcer Perforation | 1 | 2005 | 16 | 0.240 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2005 | 21 | 0.240 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2025 | 27 | 0.240 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 5468 | 0.240 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 1410 | 0.230 |
Why?
|
| Hospitalization | 3 | 2021 | 1898 | 0.230 |
Why?
|
| Bacteria | 2 | 2019 | 538 | 0.230 |
Why?
|
| Stomach Ulcer | 1 | 2005 | 94 | 0.230 |
Why?
|
| Neoplasm Staging | 4 | 2022 | 1388 | 0.220 |
Why?
|
| Medical Marijuana | 1 | 2024 | 6 | 0.220 |
Why?
|
| Multicenter Studies as Topic | 1 | 2025 | 291 | 0.220 |
Why?
|
| Canada | 1 | 2025 | 347 | 0.220 |
Why?
|
| Electronic Health Records | 3 | 2017 | 797 | 0.220 |
Why?
|
| Pregnancy Complications | 1 | 2009 | 550 | 0.220 |
Why?
|
| Oxadiazoles | 1 | 2023 | 25 | 0.210 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 2 | 2021 | 7 | 0.210 |
Why?
|
| Adolescent | 8 | 2023 | 20525 | 0.210 |
Why?
|
| Physicians, Primary Care | 1 | 2024 | 98 | 0.210 |
Why?
|
| Sacroiliitis | 1 | 2022 | 1 | 0.200 |
Why?
|
| Needs Assessment | 1 | 2024 | 183 | 0.200 |
Why?
|
| Health Services Needs and Demand | 1 | 2024 | 179 | 0.200 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2024 | 138 | 0.200 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 3992 | 0.190 |
Why?
|
| Erythema Nodosum | 1 | 2022 | 1 | 0.190 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2022 | 4 | 0.190 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 2297 | 0.190 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2024 | 770 | 0.190 |
Why?
|
| Endoscopy, Digestive System | 2 | 2014 | 156 | 0.190 |
Why?
|
| Uveitis | 1 | 2022 | 38 | 0.190 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 678 | 0.190 |
Why?
|
| Time Factors | 5 | 2021 | 6585 | 0.190 |
Why?
|
| Chronic Disease | 3 | 2021 | 1255 | 0.180 |
Why?
|
| Arthritis | 1 | 2022 | 86 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 2 | 2023 | 1069 | 0.180 |
Why?
|
| Calbindin 2 | 1 | 2021 | 18 | 0.180 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2022 | 82 | 0.180 |
Why?
|
| Budesonide | 1 | 2021 | 21 | 0.180 |
Why?
|
| Tissue Adhesions | 1 | 2021 | 30 | 0.180 |
Why?
|
| Metronidazole | 1 | 2021 | 156 | 0.170 |
Why?
|
| Genome-Wide Association Study | 3 | 2024 | 1868 | 0.170 |
Why?
|
| Texas | 4 | 2019 | 3703 | 0.170 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 288 | 0.170 |
Why?
|
| Abdomen | 1 | 2021 | 136 | 0.170 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 2165 | 0.160 |
Why?
|
| Adult Stem Cells | 1 | 2020 | 54 | 0.160 |
Why?
|
| Intestinal Obstruction | 1 | 2021 | 97 | 0.160 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 463 | 0.160 |
Why?
|
| Surgical Procedures, Operative | 1 | 2021 | 190 | 0.150 |
Why?
|
| Sulfur-Reducing Bacteria | 1 | 2018 | 2 | 0.150 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 153 | 0.150 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 293 | 0.150 |
Why?
|
| Mass Screening | 2 | 2017 | 836 | 0.150 |
Why?
|
| Methotrexate | 2 | 2012 | 354 | 0.150 |
Why?
|
| Colitis, Microscopic | 1 | 2018 | 15 | 0.150 |
Why?
|
| Intestine, Small | 1 | 2021 | 317 | 0.150 |
Why?
|
| Quality of Health Care | 1 | 2021 | 421 | 0.150 |
Why?
|
| Ambulatory Care | 1 | 2021 | 415 | 0.150 |
Why?
|
| Glucocorticoids | 1 | 2021 | 402 | 0.140 |
Why?
|
| Gelsolin | 1 | 2017 | 13 | 0.140 |
Why?
|
| Risk Assessment | 3 | 2014 | 3711 | 0.140 |
Why?
|
| Actin Cytoskeleton | 1 | 2017 | 49 | 0.140 |
Why?
|
| Primary Health Care | 1 | 2024 | 803 | 0.140 |
Why?
|
| Hemoglobins | 1 | 2019 | 321 | 0.140 |
Why?
|
| Biological Therapy | 1 | 2017 | 24 | 0.140 |
Why?
|
| Ileum | 1 | 2017 | 136 | 0.140 |
Why?
|
| Certolizumab Pegol | 1 | 2017 | 8 | 0.140 |
Why?
|
| Stomach Neoplasms | 1 | 2023 | 560 | 0.140 |
Why?
|
| Adalimumab | 1 | 2017 | 25 | 0.130 |
Why?
|
| Data Mining | 1 | 2017 | 58 | 0.130 |
Why?
|
| Withholding Treatment | 1 | 2017 | 70 | 0.130 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 315 | 0.130 |
Why?
|
| Adenoma | 2 | 2016 | 143 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2024 | 2936 | 0.130 |
Why?
|
| HLA-DRB1 Chains | 1 | 2016 | 46 | 0.130 |
Why?
|
| Pneumonia | 1 | 2020 | 343 | 0.130 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2016 | 65 | 0.130 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2016 | 83 | 0.130 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 165 | 0.130 |
Why?
|
| Smoking | 2 | 2024 | 1136 | 0.120 |
Why?
|
| Heart-Assist Devices | 1 | 2005 | 1094 | 0.120 |
Why?
|
| Focus Groups | 1 | 2017 | 212 | 0.120 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 267 | 0.120 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 289 | 0.120 |
Why?
|
| Stress, Physiological | 1 | 2017 | 271 | 0.120 |
Why?
|
| Case-Control Studies | 3 | 2018 | 3650 | 0.120 |
Why?
|
| Fatty Liver | 1 | 2017 | 215 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 560 | 0.120 |
Why?
|
| Early Detection of Cancer | 2 | 2019 | 413 | 0.120 |
Why?
|
| Biomarkers | 3 | 2022 | 3430 | 0.120 |
Why?
|
| Blood Cells | 1 | 2015 | 55 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2019 | 571 | 0.120 |
Why?
|
| Prognosis | 3 | 2017 | 5073 | 0.110 |
Why?
|
| Alopecia | 1 | 2015 | 41 | 0.110 |
Why?
|
| Fatty Acids | 1 | 2017 | 371 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2019 | 6591 | 0.110 |
Why?
|
| Phenotype | 3 | 2024 | 4552 | 0.110 |
Why?
|
| Biopsy | 4 | 2020 | 1302 | 0.110 |
Why?
|
| Medical Records | 1 | 2015 | 193 | 0.110 |
Why?
|
| Saliva | 1 | 2015 | 133 | 0.110 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2021 | 407 | 0.110 |
Why?
|
| Educational Status | 1 | 2015 | 298 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 757 | 0.110 |
Why?
|
| Helicobacter pylori | 1 | 2023 | 1333 | 0.110 |
Why?
|
| Esophagus | 1 | 2015 | 233 | 0.110 |
Why?
|
| Colonic Polyps | 1 | 2015 | 83 | 0.110 |
Why?
|
| Helicobacter Infections | 1 | 2023 | 1276 | 0.110 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2013 | 14 | 0.100 |
Why?
|
| Colostomy | 1 | 2013 | 28 | 0.100 |
Why?
|
| Stem Cells | 1 | 2018 | 752 | 0.100 |
Why?
|
| Ileostomy | 1 | 2013 | 31 | 0.100 |
Why?
|
| Linear Models | 1 | 2015 | 723 | 0.100 |
Why?
|
| Epithelial Cells | 1 | 2017 | 936 | 0.100 |
Why?
|
| Recurrence | 1 | 2017 | 1470 | 0.100 |
Why?
|
| Azathioprine | 1 | 2012 | 57 | 0.100 |
Why?
|
| Mercaptopurine | 1 | 2012 | 72 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2017 | 1004 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 920 | 0.100 |
Why?
|
| United Kingdom | 2 | 2024 | 238 | 0.100 |
Why?
|
| Leukocyte Count | 1 | 2012 | 259 | 0.100 |
Why?
|
| Sex Factors | 1 | 2015 | 1386 | 0.090 |
Why?
|
| Repressor Proteins | 1 | 2016 | 869 | 0.090 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2011 | 18 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2012 | 181 | 0.090 |
Why?
|
| Radiography | 1 | 2013 | 825 | 0.090 |
Why?
|
| Meat | 1 | 2011 | 48 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 717 | 0.090 |
Why?
|
| Fluticasone | 1 | 2010 | 15 | 0.090 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2011 | 68 | 0.090 |
Why?
|
| Pelvic Neoplasms | 1 | 2011 | 24 | 0.090 |
Why?
|
| Dietary Fiber | 1 | 2011 | 83 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 393 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 1623 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2014 | 479 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2013 | 249 | 0.080 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2010 | 19 | 0.080 |
Why?
|
| Dietary Carbohydrates | 1 | 2011 | 117 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 682 | 0.080 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 484 | 0.080 |
Why?
|
| Ribavirin | 1 | 2010 | 89 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2012 | 419 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 162 | 0.080 |
Why?
|
| Esophagoscopy | 1 | 2010 | 165 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2012 | 400 | 0.080 |
Why?
|
| Fruit | 1 | 2011 | 237 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 2570 | 0.080 |
Why?
|
| Dietary Fats | 1 | 2011 | 299 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2173 | 0.080 |
Why?
|
| Interferons | 1 | 2010 | 146 | 0.080 |
Why?
|
| Dietary Proteins | 1 | 2011 | 252 | 0.080 |
Why?
|
| Thalidomide | 1 | 2009 | 40 | 0.080 |
Why?
|
| Hyperplasia | 2 | 2022 | 202 | 0.080 |
Why?
|
| Vegetables | 1 | 2011 | 275 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2022 | 316 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 3088 | 0.070 |
Why?
|
| Protective Factors | 2 | 2021 | 92 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 1070 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 1485 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2015 | 950 | 0.070 |
Why?
|
| Breast Feeding | 1 | 2009 | 244 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 3031 | 0.070 |
Why?
|
| Pregnancy | 2 | 2010 | 7536 | 0.070 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2009 | 244 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2011 | 1487 | 0.060 |
Why?
|
| Cause of Death | 2 | 2021 | 507 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2009 | 625 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3843 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2017 | 4907 | 0.060 |
Why?
|
| Drug Substitution | 1 | 2024 | 20 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2010 | 824 | 0.060 |
Why?
|
| Fractures, Bone | 2 | 2016 | 212 | 0.050 |
Why?
|
| Indans | 1 | 2023 | 56 | 0.050 |
Why?
|
| Linkage Disequilibrium | 1 | 2024 | 333 | 0.050 |
Why?
|
| Gastroscopy | 1 | 2023 | 100 | 0.050 |
Why?
|
| Metaplasia | 1 | 2023 | 218 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2021 | 15 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 562 | 0.050 |
Why?
|
| Cost Savings | 1 | 2021 | 75 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2022 | 442 | 0.040 |
Why?
|
| Urologic Surgical Procedures | 1 | 2021 | 59 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2021 | 281 | 0.040 |
Why?
|
| Neutrophils | 1 | 2022 | 401 | 0.040 |
Why?
|
| Symptom Flare Up | 1 | 2020 | 24 | 0.040 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2021 | 62 | 0.040 |
Why?
|
| 3T3 Cells | 1 | 2020 | 122 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2022 | 340 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 162 | 0.040 |
Why?
|
| Food Analysis | 1 | 2019 | 28 | 0.040 |
Why?
|
| Brachytherapy | 1 | 2020 | 92 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2021 | 777 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 327 | 0.040 |
Why?
|
| Actinomyces | 1 | 2018 | 4 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 563 | 0.040 |
Why?
|
| Actinobacteria | 1 | 2018 | 13 | 0.040 |
Why?
|
| Bacillus | 1 | 2018 | 37 | 0.040 |
Why?
|
| Pneumococcal Vaccines | 1 | 2020 | 172 | 0.040 |
Why?
|
| Child | 1 | 2019 | 25768 | 0.040 |
Why?
|
| Clone Cells | 1 | 2018 | 180 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 738 | 0.040 |
Why?
|
| Alarmins | 1 | 2017 | 5 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2017 | 45 | 0.040 |
Why?
|
| Cell Separation | 1 | 2018 | 234 | 0.040 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2017 | 55 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 500 | 0.030 |
Why?
|
| Software | 1 | 2022 | 735 | 0.030 |
Why?
|
| Feces | 1 | 2021 | 788 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 2017 | 188 | 0.030 |
Why?
|
| Cell Death | 1 | 2017 | 252 | 0.030 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2016 | 14 | 0.030 |
Why?
|
| Sorting Nexins | 1 | 2016 | 8 | 0.030 |
Why?
|
| Receptors, CXCR6 | 1 | 2016 | 14 | 0.030 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2016 | 18 | 0.030 |
Why?
|
| Tenascin | 1 | 2016 | 32 | 0.030 |
Why?
|
| Receptors, Interleukin | 1 | 2016 | 36 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2018 | 369 | 0.030 |
Why?
|
| Receptors, Chemokine | 1 | 2016 | 49 | 0.030 |
Why?
|
| Adenylyl Cyclases | 1 | 2016 | 89 | 0.030 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2016 | 41 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 111 | 0.030 |
Why?
|
| Public Health Surveillance | 1 | 2016 | 45 | 0.030 |
Why?
|
| Organizational Innovation | 1 | 2016 | 48 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2016 | 106 | 0.030 |
Why?
|
| Receptors, Virus | 1 | 2016 | 110 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2017 | 834 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2239 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2009 | 8589 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 544 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1596 | 0.030 |
Why?
|
| Regional Medical Programs | 1 | 2015 | 17 | 0.030 |
Why?
|
| Transfection | 1 | 2017 | 1092 | 0.030 |
Why?
|
| Vascular Surgical Procedures | 1 | 2021 | 559 | 0.030 |
Why?
|
| Patient Acuity | 1 | 2015 | 67 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2016 | 105 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2015 | 63 | 0.030 |
Why?
|
| Mesalamine | 1 | 2015 | 6 | 0.030 |
Why?
|
| Cell Survival | 1 | 2017 | 889 | 0.030 |
Why?
|
| Autophagy-Related Proteins | 1 | 2015 | 36 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1621 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2015 | 239 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 888 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 246 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2015 | 133 | 0.030 |
Why?
|
| Leadership | 1 | 2016 | 246 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 366 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2017 | 1707 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 267 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 606 | 0.030 |
Why?
|
| Venous Thromboembolism | 1 | 2016 | 179 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2020 | 1068 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 1571 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 76 | 0.020 |
Why?
|
| Mitochondria | 1 | 2017 | 744 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2014 | 418 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 389 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2013 | 235 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2554 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 2091 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2018 | 2027 | 0.020 |
Why?
|
| Pain | 1 | 2014 | 482 | 0.020 |
Why?
|
| Inflammation | 1 | 2018 | 1591 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 616 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2014 | 634 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2014 | 449 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2017 | 3994 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2015 | 1069 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 1974 | 0.020 |
Why?
|
| Transcriptome | 1 | 2015 | 1136 | 0.020 |
Why?
|
| Animals | 2 | 2020 | 36432 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 4795 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 2658 | 0.020 |
Why?
|
| Mice | 1 | 2020 | 18954 | 0.010 |
Why?
|